It was superior and resulted in sustained weight loss from baseline compared with dulaglutide, exenatide (weekly), sitagliptin and insulin glargine for all comparisons
Common side effects of both drugs include nausea, vomiting, diarrhea, abdominal pain, and constipation, with specific precautions against using either medication for patients with a history (or family history) of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
Some are in the methylation pathway and others are in the GSH production pathway
For further examples of peptide synergy, see our article on Sermorelin & Tesamorelin: Growth Hormone Peptides for Longevity
Lowering BP to target cuts the rate of loss of eGFR in half, and adding a RAASi, as done in the Irbesartan Diabetic Nephropathy Trial, further reduced this rate considerably (Table 4)